Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 10, 2016 8:34 AM ET


Company Overview of Arteriocyte, Inc.

Company Overview

Arteriocyte, Inc., a clinical stage biotechnology company, develops stem cell and tissue engineering based therapies. It offers platelet rich plasma processing, automated cord blood processing, autologous stem cell therapy, allogeneic stem cell therapy, cell delivery and localization, protein co-delivery, cellular expansion, and therapeutic angiogenesis based solutions. The company also provides autologous platelet separator systems, sterile disposables, demineralized bone matrix powder, and demineralized bone matrix gel; and hematopoietic stem cell expansion kits for research applications. In addition, it develops cell therapy and tissue engineering technologies for cardiovascular, orthoped...

7100 Euclid Avenue

Suite 270

Cleveland, OH 44103

United States

Founded in 2004





Key Executives for Arteriocyte, Inc.

Chief Executive Officer
Co-Founder and Chief Medical Officer
Chief Financial Officer and Chief Operating Officer
Vice President and General Manager of Research & Development
Vice President of Clinical and Regulatory Affairs
Compensation as of Fiscal Year 2015.

Arteriocyte, Inc. Key Developments

Arteriocyte, Inc. Receives FDA IDE Approval to Initiate Clinical Evaluation of MAGELLAN(R) Bio-Bandage(TM)

Arteriocyte, Inc. announced approval from the Federal Drug Administration (FDA) to initiate a Phase I, clinical trial using its MAGELLAN(R) Bio-Bandage(TM) technology in the treatment of Acute Deep Partial Thickness Thermal Injuries. The FDA Investigational Device Exemption (IDE 15921) allows the company to initiate clinical evaluation of Autologous Platelet Rich Plasma use in thermal injuries. The MAGELLAN(R) Bio-Bandage(TM) is an autologous intervention designed to minimize the severity of the burn wound, reduce the immediate need for surgical intervention when a skin graft is required, and improve the wound's healing trajectory.

Similar Private Companies By Industry

Company Name Region
SWITCH Biotech LLC United States
Prospect Genomics, Inc. United States
Exiqon Diagnostics, Inc. United States
Primordial Genetics Inc. United States
Vidus Ocular, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Arteriocyte, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at